Royal Sense Ltd
Incorporated in 2023, Royal Sense Ltd specializes in medical device and pharmaceutical trading.[1]
- Market Cap ₹ 56.7 Cr.
- Current Price ₹ 106
- High / Low ₹ 310 / 85.0
- Stock P/E 7.93
- Book Value ₹ 75.7
- Dividend Yield 0.00 %
- ROCE 26.2 %
- ROE 21.0 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| 18 | 62 | 103 | |
| 16 | 53 | 92 | |
| Operating Profit | 2 | 9 | 11 |
| OPM % | 13% | 14% | 11% |
| 0 | 0 | 0 | |
| Interest | 0 | 0 | 1 |
| Depreciation | 0 | 0 | 0 |
| Profit before tax | 2 | 9 | 10 |
| Tax % | 28% | 27% | 28% |
| 2 | 6 | 7 | |
| EPS in Rs | 3.24 | 12.74 | 13.36 |
| Dividend Payout % | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 67% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 13% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -49% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 20% |
| Last Year: | 21% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Equity Capital | 5 | 5 | 5 |
| Reserves | 13 | 23 | 35 |
| 2 | 3 | 13 | |
| 1 | 5 | 8 | |
| Total Liabilities | 21 | 36 | 61 |
| 0 | 2 | 2 | |
| CWIP | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 |
| 20 | 33 | 59 | |
| Total Assets | 21 | 36 | 61 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| -4 | 1 | -13 | |
| -1 | -2 | -0 | |
| 13 | 3 | 5 | |
| Net Cash Flow | 9 | 2 | -8 |
| Free Cash Flow | -4 | -0 | -14 |
| CFO/OP | -144% | 21% | -110% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Debtor Days | 66 | 86 | 101 |
| Inventory Days | 63 | ||
| Days Payable | 10 | ||
| Cash Conversion Cycle | 66 | 86 | 153 |
| Working Capital Days | 187 | 86 | 126 |
| ROCE % | 35% | 26% |
Insights
In beta| Mar 2024 | Mar 2025 | |
|---|---|---|
| Geographic Presence (States/UTs) count ・Standalone data |
|
|
| Permanent Employees count ・Standalone data |
||
| New Products Launched count ・Standalone data |
||
| Satisfied Customers count ・Standalone data |
||
| Total Product Portfolio count ・Standalone data |
||
| US FDA Approvals Obtained count ・Standalone data |
||
Extracted by Screener AI
Documents
Announcements
-
Board Meeting Outcome for Outcome Of Board Meeting Held On 17Th July, 2026
17 Jul - Board approved capital doubling, ₹500 crore fundraise, ₹200 crore acquisitions, and overseas branch proposal on 17 July 2026.
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 16 Jul
-
Board Meeting Intimation for Prior Intimation For Board Meeting To Be Held On 17Th July, 2026
14 Jul - Board meeting on 17 July 2026 to consider higher authorised capital and fundraising.
-
Appointment of Company Secretary and Compliance Officer
13 Jul - Ms. Somya Arora appointed Company Secretary from July 13, 2026.
- Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011. 4 Jul
Business Overview:[1][2]
RSL deals in Advanced medical devices, pharmaceuticals, diagnostics, and offers surgical solutions. It provides hospitals, laboratories, clinics, and institutions
with products like surgical accessories, instruments, equipment, consumables,
reagents, diagnostic kits, and disposable
medical supplies